LDRT Combined With Toripalimab and Chemotherapy for Recurrent/Metastatic NPC

This study aims to evaluate the efficacy and safety of LDRT combined with toripalimab and GP chemotherapy in patients with recurrent or metastatic nasopharyngeal carcinoma through a prospective, open-label, single-arm Phase II clinical trial.

Trial Details

NCT ID

NCT07325539

Phase

PHASE2

Sponsor

Sun Yat-sen University

Status

RECRUITING

Cancer Type

Nasopharyngeal Head and Neck Cancer

Interventions

Gemcitabine(GEM)
Cisplatin
Toripalimab
LDRT

Locations (sample)

Guangzhou, Guangdong, China|23.11667,113.25
Shenzhen, Guangdong, China|22.54554,114.0683

Key Eligibility Criteria

Age: 18-65 years old.
Histologically confirmed non-keratinizing nasopharyngeal carcinoma (WHO Type II or III).
ECOG Performance Status score of 0-1.
At least one measurable lesion as per RECIST v1.1 criteria.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Nasopharyngeal Head and Neck Cancer Trials on Trialify →